Glaukos is a global pioneer in the ophthalmic market with novel therapies that provide sustainable solutions for important clinical needs. This company is focussed on developing and leading the global ophthalmic market with innovative therapies for corneal health, glaucoma, and retinal diseases through continual innovation and investment.
Glaukos’ expansion into the corneal health space starts with the treatment of keratoconus. Glaukos now offers the iLinkV corneal cross-linking platform which comprises of proprietary VibeX Rapid riboflavin and the ultra-violet A (UVA) light from the KXL System for the treatment of progressive keratoconus – proven technology that addresses the underlying pathophysiology of this vision threatening disease and aims to slow or halt progression.
Contact: Glaukos Account Manager
